Macrophage activation syndrome (MAS) is a potentially life-threatening complication of rheumatic disorders that occurs most commonly in systemic juvenile idiopathic arthritis. In recent years, there have been several advances in the understanding of the pathophysiology of MAS. Furthermore, new classification criteria have been developed. Although the place of cytokine blockers in the management of MAS is still unclear, interleukin-1 inhibitors represent a promising adjunctive therapy, particularly in refractory cases.

Macrophage Activation Syndrome

Ravelli, Angelo;Davì, Sergio;Minoia, Francesca;Martini, Alberto;
2015-01-01

Abstract

Macrophage activation syndrome (MAS) is a potentially life-threatening complication of rheumatic disorders that occurs most commonly in systemic juvenile idiopathic arthritis. In recent years, there have been several advances in the understanding of the pathophysiology of MAS. Furthermore, new classification criteria have been developed. Although the place of cytokine blockers in the management of MAS is still unclear, interleukin-1 inhibitors represent a promising adjunctive therapy, particularly in refractory cases.
File in questo prodotto:
File Dimensione Formato  
2015_Macrophage Activation Syndrome.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 231.6 kB
Formato Adobe PDF
231.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/937977
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 110
  • ???jsp.display-item.citation.isi??? 110
social impact